In real-world studies, GLP-1 RAs have consistently been associated with reduced cardiovascular risk in people with T2D [23–28], including reduced incidence of stroke (HRs between 0.65 and 0.74) and MI (HRs between 0.63 and 0.86). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.